Despite encouraging results from a preclinical testing, the selective PDE inhibitors are used sporadically in patients with ARDS or sepsis (Table 3), except for the ongoing studies on COVID-19 (see Chapter 7). Here, ALDH7A1 is linked to COVID-19.